COVID-19 恢复期血浆清除了瑞德西韦难治的先天性心脏病婴儿中的 SARS-CoV-2。
COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.
机构信息
Division of Cardiology.
Division of Infectious Disease, Department of Pediatrics, Children's Healthcare of Atlanta, and.
出版信息
Blood Adv. 2020 Sep 22;4(18):4278-4281. doi: 10.1182/bloodadvances.2020002507.
Abstract
COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.
摘要
COVID-19 恢复期血浆（CP）可能是一种安全有效的治疗选择，用于治疗对瑞德西韦无反应的 SARS-CoV-2 感染。尽管婴儿的免疫系统和供体的变异性可能受益于 CP，但这强调了在使用之前需要对其进行特征描述。
Zotero 插件